| Item Type | Name |
|
Academic Article
|
Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study.
|
|
Academic Article
|
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
|
|
Academic Article
|
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
|
|
Academic Article
|
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
|
|
Concept
|
Tamoxifen
|
|
Academic Article
|
Neoadjuvant endocrine therapy as a drug development strategy.
|
|
Academic Article
|
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
|
|
Academic Article
|
Tamoxifen-induced hypercalcemia in breast cancer.
|
|
Academic Article
|
Tamoxifen dosage and bioequivalence: a correction.
|
|
Academic Article
|
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
|
|
Academic Article
|
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.
|
|
Academic Article
|
The place of chemotherapy in the treatment of early breast cancer.
|
|
Academic Article
|
Tamoxifen's clinical applications: old and new.
|
|
Academic Article
|
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
|
|
Academic Article
|
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
|
|
Academic Article
|
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
|
|
Academic Article
|
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
|
|
Academic Article
|
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
|
|
Academic Article
|
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
|
|
Academic Article
|
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
|
|
Academic Article
|
Tamoxifen versus aromatase inhibitors for breast cancer prevention.
|
|
Academic Article
|
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
|
|
Academic Article
|
Letrozole or tamoxifen in early breast cancer.
|
|
Academic Article
|
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
|
|
Academic Article
|
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
|
|
Academic Article
|
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
|
|
Academic Article
|
Tamoxifen therapy for patients with breast cancer.
|
|
Academic Article
|
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
|
|
Academic Article
|
Hormonal therapy for metastatic male breast cancer.
|
|
Academic Article
|
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
|
|
Academic Article
|
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
|
|
Academic Article
|
Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
|
|
Academic Article
|
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
|
|
Academic Article
|
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
|
|
Academic Article
|
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
|
|
Academic Article
|
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
|
|
Academic Article
|
ATAC trial did not report interim results.
|
|
Academic Article
|
Role of anastrozole in adjuvant therapy for postmenopausal patients.
|
|
Academic Article
|
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
|
|
Academic Article
|
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
|
|
Academic Article
|
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
|
|
Academic Article
|
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
|
|
Academic Article
|
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
|
|
Academic Article
|
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
|
|
Academic Article
|
Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial.
|
|
Academic Article
|
Anastrozole.
|
|
Academic Article
|
Predictive algorithms for adjuvant therapy: TransATAC.
|
|
Academic Article
|
Aromatase inhibitors in premenopausal breast cancer.
|
|
Academic Article
|
Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy.
|
|
Academic Article
|
Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.
|
|
Academic Article
|
Role of adjuvant chemotherapy in male breast cancer.
|
|
Academic Article
|
Bilateral primary breast cancer in patients treated with adjuvant therapy.
|
|
Academic Article
|
Trioxifene mesylate in the treatment of advanced breast cancer.
|
|
Academic Article
|
Adjuvant chemotherapy for breast cancer.
|
|
Academic Article
|
Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'.
|
|
Academic Article
|
Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
|
|
Academic Article
|
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
|
|
Academic Article
|
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
|
|
Academic Article
|
Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
|
|
Academic Article
|
Phase I trial of droloxifene in patients with metastatic breast cancer.
|
|
Academic Article
|
Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer.
|
|
Academic Article
|
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
|
|
Academic Article
|
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
|
|
Academic Article
|
Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
|
|
Academic Article
|
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
|
|
Academic Article
|
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
|
|
Academic Article
|
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
|
|
Academic Article
|
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
|
|
Academic Article
|
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
|
|
Academic Article
|
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
|
|
Academic Article
|
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
|
|
Academic Article
|
Current developments in hormonal therapy of breast cancer.
|
|
Academic Article
|
How rapidly do oncologists respond to clinical trial data?
|
|
Academic Article
|
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
|
|
Academic Article
|
Are aromatase inhibitors superior to antiestrogens?
|
|
Academic Article
|
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
|
|
Academic Article
|
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
|
|
Academic Article
|
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
|
|
Academic Article
|
Anastrozole for breast cancer: recent advances and ongoing challenges.
|
|
Academic Article
|
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
|
|
Academic Article
|
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
|
|
Academic Article
|
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
|
|
Academic Article
|
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
|
|
Academic Article
|
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
|
|
Academic Article
|
Hormonal therapy with tamoxifen in male breast cancer.
|
|
Academic Article
|
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
|
|
Academic Article
|
Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience.
|
|
Academic Article
|
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
|
|
Academic Article
|
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
|
|
Academic Article
|
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
|
|
Academic Article
|
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
|
|
Academic Article
|
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
|
|
Academic Article
|
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
|
|
Academic Article
|
Hormonal therapy in early and advanced breast cancer.
|
|
Academic Article
|
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
|
|
Academic Article
|
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
|
|
Academic Article
|
Use of tamoxifen for breast cancer: twenty-eight years later.
|
|
Academic Article
|
Aromatase inhibitors in metastatic breast cancer.
|
|
Academic Article
|
Differences in toxicity findings for antiestrogens.
|
|
Academic Article
|
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.
|
|
Academic Article
|
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
|
|
Academic Article
|
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
|
|
Academic Article
|
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
|
|
Academic Article
|
Complete remission with combination chemotherapy in metastatic breast carcinoma.
|
|
Academic Article
|
Letrozole in breast cancer.
|
|
Academic Article
|
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
|
|
Academic Article
|
Letrozole or tamoxifen in early breast cancer.
|
|
Academic Article
|
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
|
|
Academic Article
|
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
|
|
Academic Article
|
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
|
|
Academic Article
|
Tamoxifen
|
|
Academic Article
|
E17. Are aromatase inhibitors superior to tamoxifen after the menopause
|
|
Academic Article
|
Evaluation of tamoxifen in chemotherapy resistant metastatic breast cancer
|
|
Academic Article
|
Letrozole improved disease-free survival in postmenopausal women after tamoxifen treatment for breast cancer
|
|
Academic Article
|
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
|